119 related articles for article (PubMed ID: 18572390)
1. Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation.
Ustun C; DeRemer DL; Steele JC; Forseen C; Fisher JF; Jillella AP
Int J Antimicrob Agents; 2008 Oct; 32(4):365-6. PubMed ID: 18572390
[No Abstract] [Full Text] [Related]
2. Breakthrough fungemia due to Candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin - report of 5 cases.
Krcmery V; Demitrovicova A; Kisac P
J Chemother; 2011 Oct; 23(5):310-1. PubMed ID: 22005067
[No Abstract] [Full Text] [Related]
3. Structure-activity relationships of 3-methyl and 3,3-dimethyl analogs of 2-(2,4-difluorophenyl)-3-(omega-substituted alkyl)sulfonyl-1-(1H-1,2,4-triazol-1-yl)-2-propanols.
Miyauchi H; Kozuki K; Tanio T; Ohashi N
Chem Pharm Bull (Tokyo); 1996 Apr; 44(4):785-92. PubMed ID: 8681411
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.
Vehreschild JJ; Krüger K; Kurzai O; Wickenhauser C; Behringer K; Töx U; Cornely OA
Mycoses; 2006; 49 Suppl 1():42-7. PubMed ID: 16961582
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation.
Mousset S; Bug G; Heinz WJ; Tintelnot K; Rickerts V
Transpl Infect Dis; 2010 Jun; 12(3):261-4. PubMed ID: 19954497
[TBL] [Abstract][Full Text] [Related]
6. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.
Störzinger D; Lichtenstern C; Swoboda S; Weigand MA; Hoppe-Tichy T
Mycoses; 2008 Sep; 51 Suppl 2():52-7. PubMed ID: 18721332
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
9. Molecular assay to detect nosocomial fungal infections in intensive care units.
Badiee P; Alborzi A; Joukar M
Eur J Intern Med; 2011 Dec; 22(6):611-5. PubMed ID: 22075290
[TBL] [Abstract][Full Text] [Related]
10. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole.
Kuipers S; Brüggemann RJ; de Sévaux RG; Heesakkers JP; Melchers WJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2011 Jul; 55(7):3564-6. PubMed ID: 21502625
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
Imhof A; Balajee SA; Fredricks DN; Englund JA; Marr KA
Clin Infect Dis; 2004 Sep; 39(5):743-6. PubMed ID: 15356792
[TBL] [Abstract][Full Text] [Related]
13. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
Cordonnier C; Maury S; Pautas C; Bastié JN; Chehata S; Castaigne S; Kuentz M; Bretagne S; Ribaud P
Bone Marrow Transplant; 2004 May; 33(9):943-8. PubMed ID: 15034546
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation.
Chandrasekar P
Med Mycol; 2009; 47 Suppl 1():S349-54. PubMed ID: 18663660
[TBL] [Abstract][Full Text] [Related]
15. Multiple-triazole-resistant aspergillosis.
Verweij PE; Mellado E; Melchers WJ
N Engl J Med; 2007 Apr; 356(14):1481-3. PubMed ID: 17409336
[No Abstract] [Full Text] [Related]
16. [Invasive fungal infections in patients after liver transplantation].
Fischer L; Sterneck M
Mycoses; 2005; 48 Suppl 1():27-35. PubMed ID: 15826284
[TBL] [Abstract][Full Text] [Related]
17. Bile aspiration for diagnosis of Candida glabrata cholecystitis.
Misselwitz B; Imhof A; Schneemann M
Infection; 2008 Mar; 36(2):189-90. PubMed ID: 18327680
[No Abstract] [Full Text] [Related]
18. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms.
Cendejas-Bueno E; Borobia AM; Gomez-Lopez A; Escosa-García L; Río-García M; Plaza D; García-Rodriguez J; Carcas-Sansuán A
Int J Antimicrob Agents; 2016 May; 47(5):410-1. PubMed ID: 27056297
[No Abstract] [Full Text] [Related]
19. [Vertebral aspergillosis in a cirrhotic patient: an uncommon cause of spondylitis].
Fernandez de Orueta L; Andrés R; Elías T; Pintado V
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):219-20. PubMed ID: 22365181
[No Abstract] [Full Text] [Related]
20. Novel medicine to prevent fungal infections.
FDA Consum; 2006; 40(6):2. PubMed ID: 17333551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
